MARKET

VERA

VERA

Vera Therapeutics, Inc.
NASDAQ
32.54
-0.80
-2.40%
After Hours: 32.72 +0.18 +0.55% 19:51 09/25 EDT
OPEN
33.34
PREV CLOSE
33.34
HIGH
33.44
LOW
32.46
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
56.05
52 WEEK LOW
23.05
MARKET CAP
2.34B
P/E (TTM)
-5.5502
1D
5D
1M
3M
1Y
5Y
1D
Vera Therapeutics Down Over 8%, On Track for Largest Percent Decrease Since November 2025 -- Data Talk
Dow Jones · 2d ago
Weekly Report: what happened at VERA last week (0914-0918)?
Weekly Report · 5d ago
Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead
NASDAQ · 09/18 14:44
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday
Benzinga · 09/17 15:58
2 ‘Strong Buy’ Stocks Where a Short Squeeze Could Be Brewing
TipRanks · 09/17 09:58
Jefferies Sticks to Its Buy Rating for Vera Therapeutics (VERA)
TipRanks · 09/16 13:15
Wedbush Sticks to Its Hold Rating for Vera Therapeutics (VERA)
TipRanks · 09/16 12:26
Analysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Vera Therapeutics (VERA)
TipRanks · 09/16 11:10
More
About VERA
Vera Therapeutics, Inc. is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.

Webull offers Vera Therapeutics, Inc stock information, including NASDAQ: VERA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERA stock methods without spending real money on the virtual paper trading platform.